Marshall Fordyce Sells 16,925 Shares of Vera Therapeutics (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 16,925 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $710,511.50. Following the completion of the sale, the chief executive officer owned 257,163 shares in the company, valued at $10,795,702.74. The trade was a 6.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Vera Therapeutics Price Performance

Shares of VERA opened at $42.35 on Friday. The company has a quick ratio of 12.21, a current ratio of 12.21 and a debt-to-equity ratio of 0.19. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $56.05. The stock has a market capitalization of $2.97 billion, a P/E ratio of -10.61 and a beta of 1.16. The company has a 50 day moving average of $46.53 and a 200-day moving average of $35.35.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same period last year, the company earned ($0.72) EPS. As a group, equities research analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Key Stories Impacting Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: FDA priority review and NEJM/ASN recognition for atacicept — Vera reported positive Phase 3 ORIGIN‑3 data for atacicept in IgA nephropathy that were presented at ASN Kidney Week and published in the New England Journal of Medicine. The FDA has granted priority review for the atacicept BLA with a PDUFA date of July 7, 2026, and the company expects a potential U.S. commercial launch in mid‑2026. Management also said recent 2025 equity and debt financings leave the company well‑capitalized into and beyond approval and launch. Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
• Neutral Sentiment: Financials/earnings update — Vera released FY‑2025 results and quarterly EPS figures; one report shows EPS of ($1.39) for the quarter (slightly missing consensus by ~$0.05). The results highlight continued operating losses but the company emphasizes runway provided by recent financings. Investors will focus on how close the company is to commercialization economics once/if atacicept is approved. View Press Release
• Negative Sentiment: Concentrated insider selling — multiple senior executives (including the CEO, CFO, COO and other officers) sold shares on Feb 23 at roughly $42/share (CEO Marshall Fordyce sold ~16,925 shares; other officers also reduced holdings). Such clustered insider sales can prompt investor caution and short‑term selling pressure despite the regulatory progress. Vera Therapeutics Insider Sells

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on VERA. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a research report on Friday, December 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Vera Therapeutics in a research note on Wednesday, November 26th. Wedbush boosted their price target on Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Wednesday, January 21st. Finally, Evercore increased their price objective on Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.80.

Institutional Trading of Vera Therapeutics

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC increased its holdings in shares of Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after acquiring an additional 236 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in Vera Therapeutics during the fourth quarter worth $46,000. Aster Capital Management DIFC Ltd bought a new position in Vera Therapeutics during the fourth quarter worth $71,000. Quantbot Technologies LP acquired a new position in shares of Vera Therapeutics in the second quarter valued at $51,000. Finally, Sandia Investment Management LP bought a new position in shares of Vera Therapeutics in the fourth quarter valued at about $127,000. 99.21% of the stock is owned by institutional investors and hedge funds.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.